COVID-19 had its first case in the city of Wuhan, China, in December 2019, with a few isolated cases that soon became a pandemic within a short period of time. Studies report widely varying prevalences of neurological manifestations, ranging from 3% to 35%, with a higher incidence in severe or critical cases. Neurological manifestations generally occur between the first and 14th day after the onset of respiratory symptoms. To determine the prevalence and types of neurological sequelae in post-COVID-19 patients through a literature review. A literature search was conducted in the electronic databases BVS, PubMed, and SciELO. Inclusion criteria were studies with full text availability, on patients who contracted COVID-19, published from 2019 to 2022. After applying the inclusion and exclusion criteria, 17 articles were selected, with nine eligible articles. The main results showed that COVID-19 affects the central nervous system (CNS) and can also cause exacerbated activation of the immune system, leading to stroke, depression, anxiety, encephalopathies, headaches, among others. Patient follow-up is necessary since this is a disease still under study and relatively new. This review should be updated as new sequelae or consequences may arise in the long term after the virus.
References
Gautret P, Calcagno O. Olfactory and gustatory dysfunction in COVID‐19 patients: a metanalysis study. Physiol Rep. 2020 Sep;8(18):e14578.
Marinho PRD, Cordeiro GM, Coelho HFC, Brandão SCS. Covid-19 in Brazil: a sadscenario. Cytokine Growth Factor Rev. 2021 Apr;58:51-54.
Nalbandian A. Post-acute COVID-19 syndrome. Nat Med. 2021 Apr;27:601-615.
Espíndola OM, Gomes YCP, Brandão CO, Siqueira M. Patients with covid-19 and neurological manifestations show undetectable sars-cov-2 RNA levels in the cerebrospinal fluid. Int J Infect Dis. 2020 Dec;96:567-569.
Vergara JP, Tolosa C. Covid-19: manifestaciones neurológicas. Acta Neurol Colomb. 2020;36(21):7-10.
Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy. Cureus. 2020 Mar;12(3):e7352.
Hajikhani B, Calcagno T, Nasiri MJ, Jamshidi P, Dadashi M, Goudarzi M, Eshraghi AA, Mirsaeidi M. Olfactory and gustatory dysfunction in COVID-19 patients: A meta-analysis study. Physiol Rep. 2020 Sep;8(18):e14578.
Sweid A, Hammoud B, Bekelis K, Missios S, Tjoumakaris SI, Gooch MR, et al. Cerebral ischemic and hemorrhagic complications of coronavirus disease 2019. Int J Stroke. 2020 Oct;15(7):733-742.
Fernández-de-las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado-Pérez ML, Florencio LL, Guerrero AL, et al. Headache as an acute and post-COVID-19 symptom in COVID-19 survivors: a meta-analysis of the current literature. Eur J Neurol. 2021 Nov;28(11):3820-3825.
Syahrul S, Dwipayana P, Irawan DM, Mochtar CA, Nandika D. Hemorrhagic and ischemic stroke in patients with coronavirus disease 2019: incidence, risk factors, and pathogenesis - a systematic review and meta-analysis. F1000Res. 2021;10:34.
Mutiawati E, Syahrul S, Wati DS, Sari FR, Salim MR, Candra H, et al. Anosmia and dysgeusia in SARS-CoV-2 infection: incidence and effects on covid-19 severity and mortality, and the possible pathobiology mechanisms - a systematic review and meta-analysis. F1000Res. 2021;10:40.
Deng J, Zhou F, Hou W, Silver Z, Wong CY, Chang O, et al. The prevalence of depression, anxiety, and sleep disturbances in COVID-19 patients: a meta-analysis. Ann N Y Acad Sci. 2021 Apr;1486(1):90-111.
Siow I, Lee KS, Zhang JJY, Saffari SE, Ng A, Young B. Stroke as a Neurological Complication of COVID-19: A Systematic Review and Meta-Analysis of Incidence, Outcomes and Predictors. J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105549. doi: 10.1016/j.jstrokecerebrovasdis.2020.105549. PMID: 33309482.
Dangayach NS, Gunderson T, Grewal P, et al. Acute Neurologic Complications of COVID-19 and Postacute Sequelae of COVID-19. Crit Care Clin. 2022 Jul;38(3):553-570. doi: 10.1016/j.ccc.2022.03.002. PMID: 34144913.